{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030955","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.041103+00:00","generated_at":"2026-06-08T09:05:38.185463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4","bullets":["Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.","Cash $13.4M at Sep 30; Oxford senior debt fully repaid in Q2 2023.","FDA IDE approval for Niyad (regional anticoagulant for dialysis); NEPHRO study to start Q4, data mid-2024.","July private placement raised $10M, with potential $16.3M additional upon milestone warrants.","Combined R&D and SG&A expenses $3.4M, down from $4.5M YoY; headcount reduction offset by Niyad costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030955","json":"https://secwatch.observer/filing/0001437749-23-030955.json","markdown":"https://secwatch.observer/filing/0001437749-23-030955.md","text":"https://secwatch.observer/filing/0001437749-23-030955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/0001437749-23-030955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/acrx20231107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:05:38.185463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f71835aeaa3a0ba5dbc2425eb6417aad18e24d29","claim":"TALPHERA, INC. reported the three months ended September 30, 2023 results: revenue $0.1 million, net income $1.4 million, EPS $0.08 per basic and diluted share.","evidence_excerpt":"● The cash and cash equivalents balance was $13.4 million as of September 30, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.1 million for the third quarter primarily represent the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/0001437749-23-030955-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"$1.4 million"},{"label":"EPS","value":"$0.08 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}